NSE: CONCORDBIO · 11 November 2026
- Concord Biotech has fallen 10.47% over 3 trading sessions; today's move is +0.92%.
- Concord Biotech informed the exchange that its Board of Directors approved the allotment of 10,46,16,204 fully paid-up bonus equity shares of ₹1 each. The bonus shares were issued in the proportion of 1:1 to eligible shareholders whose names appeared on the register of members as of the record date of November 4, 2026. Consequent to this corporate action, the company's paid-up share capital increased to ₹20,92,32,408.
- Trading volume was 0.24 times the 20-day average daily volume.
Concord Biotech share price: 10.47% decline over 3 trading sessions
Concord Biotech Ltd. (CONCORDBIO) traded higher by 0.92% on November 11, 2026, changing hands at ₹602.30 compared to its previous close of ₹596.80. The stock opened at ₹603.40 and moved within a day's range of ₹601.90 to ₹613.70.
While the broader Nifty benchmark advanced by 1.23%, the pharmaceutical sector index moved in the opposite direction, declining by 0.52%. Concord Biotech's modest gain stood in contrast to the broader sector's weakness, though the stock has experienced a broader correction, registering a 5-day return of -1.90% and a 20-day return of -11.06%.
Company disclosures provide ongoing context, including the completion of its Unit II formulation facility inspection in Valthera, Ahmedabad, by the USFDA with a single minor procedural observation, alongside recent financial results for the quarter ended September 30, 2026, reporting a consolidated revenue of ₹309.1 crore and profit after tax of ₹69.6 crore. However, these fundamental developments do not directly establish a confirmed trading catalyst for today's price action.
72,288 shares traded by 11 November 2026 · 10:30 AM IST. This compares with a 20-day average daily volume of 3.07 lakh shares (0.24 times). The five-day average daily volume was 4.15 lakh shares. Separately, the NSE report for 9 November 2026 showed 1.78 lakh shares delivered, representing 43.06% of that day’s traded volume. The same report recorded 36,585 trades.
No specific same-day catalyst or news event links directly to today's 0.92% gain. The move appears consistent with a mild technical recovery following recent downward price pressure, supported by low relative cash volume.
Latest Company Developments
Concord Biotech informed the exchange that its Board of Directors approved the allotment of 10,46,16,204 fully paid-up bonus equity shares of ₹1 each. The bonus shares were issued in the proportion of 1:1 to eligible shareholders whose names appeared on the register of members as of the record date of November 4, 2026. Consequent to this corporate action, the company's paid-up share capital increased to ₹20,92,32,408.
This corporate action adjusts the equity capital structure and share liquidity following the 1:1 bonus issue.
The company reported its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. Consolidated revenue from operations for the second quarter reached ₹309.1 crore, marking a 25.1% year-on-year growth compared to ₹247.1 crore in the corresponding period of the previous year. Profit after tax for the quarter stood at ₹69.6 crore, up 10.3% year-on-year.
Financial performance provides baseline metrics on revenue growth, product mix, and margin trends across API and formulation segments.
Concord Biotech announced the successful completion of a US Food and Drug Administration (USFDA) inspection at its Unit II formulation manufacturing facility located in Valthera, Ahmedabad. The inspection concluded with one minor procedural observation that was unrelated to good manufacturing practices (GMP).
Regulatory compliance at manufacturing facilities supports the continuity of international supplies and regulatory approvals in global markets.
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 5.84% on 30 September 2026. This compares with 4.40% on 30 June 2026, a change of +1.44 percentage points.
The filing reported 22 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Execution and delivery trends following the recent 1:1 bonus share allotment and record date.
- Performance of the newly launched dermatology division, Inspira, and its contribution to domestic formulation revenues.
- Commercial progress on recently approved ANDAs for Tofacitinib and MMF OS in regulated markets.
- Sustained delivery percentage, which stood at 43.06% with 1,78,251 delivery shares on the cash report date.
Other Dated Coverage
- Concord Biotech Share Price Today: Falls 11.28% in 2 Trading Sessions | 9 November 2026 — 9 November 2026
- Concord Biotech Share Price Today: Rises 12.61% in 2 Trading Sessions | 4 November 2026 — 4 November 2026
- Concord Biotech Share Price Today: Falls 10.56% in 2 Trading Sessions | 29 October 2026 — 29 October 2026
More Concord Biotech news and dated analysis →
Frequently Asked Questions
What is the latest Concord Biotech company news?
Concord Biotech informed the exchange that its Board of Directors approved the allotment of 10,46,16,204 fully paid-up bonus equity shares of ₹1 each. The bonus shares were issued in the proportion of 1:1 to eligible shareholders whose names appeared on the register of members as of the record date of November 4, 2026. Consequent to this corporate action, the company's paid-up share capital increased to ₹20,92,32,408.
How strong was Concord Biotech’s trading volume?
72,288 shares traded, 0.24 times the 20-day average daily volume. The price and volume data are dated 11 November 2026 · 10:30 AM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.